Recent Quotes (30 days)

You have no recent quotes
chg | %

AstraZeneca plc  

(Public, LON:AZN)   Watch this stock  
Find more results forAZN
+68.00 (1.42%)
Mar 16 - Close
LON real-time data - Disclaimer
Currency in GBX unless noted
Range 4,782.00 - 4,886.50
52 week 4,260.00 - 5,520.00
Open 4,785.00
Vol / Avg. 4.24M/2.31M
Mkt cap 61,638.07M*
P/E 28.95
Div/yield 133.60*
EPS 1.68*
Shares 1,266.45M
Beta     -
Inst. own     -
May 18, 2018
Q1 2018 AstraZeneca PLC Earnings Release - 7:00am BST - Add to calendar
May 18, 2018
AstraZeneca PLC Annual Shareholders Meeting Add to calendar
Mar 13, 2018
AstraZeneca PLC at Barclays Global Healthcare Conference
Mar 13, 2018
AstraZeneca PLC at Goldman Sachs European Corporate Conference
Mar 12, 2018
AstraZeneca PLC at Cowen Health care Conference
Mar 7, 2018
AstraZeneca PLC at Daiwa Investment Conference - Tokyo
Mar 6, 2018
AstraZeneca PLC Investor Roadshow - Basel
Mar 6, 2018
AstraZeneca PLC Investor Roadshow - Milan
Feb 28, 2018
AstraZeneca PLC at Shore Capital Healthcare Symposium
Feb 28, 2018
AstraZeneca PLC at Credit Suisse Global Healthcare Conference

Key stats and ratios

Q4 (Dec '17) 2017
Net profit margin 21.31% 12.63%
Operating margin 11.87% 16.37%
EBITD margin - 30.08%
Return on average assets 7.72% 4.51%
Return on average equity 35.54% 19.93%
Employees 61,100 -
CDP Score - A


1 Francis Crick Avenue Cambridge Biomedical Campus
United Kingdom - Map
+44-20-73045000 (Phone)
+44-20-76048151 (Fax)

Website links

External links

Analyst Estimates - BusinessWeek
Options - MarketWatch
Director Dealings - Yahoo Finance


AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience. In CVMD, it is expanding its portfolio into the cardiovascular-renal area with late-stage assets, such as ZS-9 and roxadustat, as well as investing to explore the benefits of its SGLT2 and GLP-1 franchises in chronic kidney disease (CKD) and heart failure (HF). The Company has approximately 40 projects in Phase I, including 29 new molecular entities (NMEs), and 11 oncology combination projects. It has approximately 40 projects in Phase II, including 25 NMEs; four significant additional indications for projects that have reached phase II, and seven oncology combination projects.

Officers and directors

Pascal Soriot Executive Director and Chief Executive Officer
Age: 57
Marc Dunoyer Executive Director, Chief Financial Officer
Age: 64
Fiona Cicconi Executive Vice-President, Human Resources
Sean Bohen M.D., Ph.D. Chief Medical Officer, Executive Vice President - Global Medicines Development
Pam P. Cheng Executive Vice President - Operations and Information Technology
Age: 45
Ruud Dobber Executive Vice President, North America
Bahija Jallal Ph.D. Executive Vice President, MedImmune
Mark Mallon Executive Vice President, Global Product and Portfolio Strategy, Global Medical Affairs & Corporate Affairs Executive Vice-President, International West
Menelas Pangalos Executive Vice President - IMED Biotech Unit and Global Business Development
Leon Wang Executive Vice President - Asia Pacific